

**Attendees:** Adriansjah Azhari (AA) Apoorv Kumar (AP), Dat Do (DD), Ladda Suwitruengrit (LS), Marcus Freire (MF), Martin Reers (MR), Nishant Vora (NV), Rachel Park (RP), Ricardo Palacios Gomez (RPG), Sai D. Prasad (SDP), Samir Desai (SD), Sekar Thangaraj (ST), Suresh Jadhav (SJ), Valeria Brizzio (VB), Yuri Vasilev (YV), and Sonia Villasenor (SV).

**Excused:** Sonia Pagliusi (SP), Raches Ella (RE)

---

The meeting started at 12:00 with an epidemiological update by AP.

- SDP presented two concepts to discuss: ongoing discussion and potential way to work with the WEF since May. WEF is interested in vaccines and COVID-19 pandemic because of the impact it is having on national government economies and national security as well.
- While US has Warp Speed and procurement contract has been issued out; and the EU, major countries have also gotten into consortium to procure vaccines directly from companies; and large countries like China and India are developing their own vaccines trying to be self-sufficient, there is a Gap between these and the rest of the countries where member companies are and countries where we supply. The gap is the way CEPI is funding projects. For example, companies with strong candidates having a lack of manufacturing capacity. AZ was funded by Gavi even though their Ph 1 data was not submitted. The concern is that other entities such as members within the network might be left behind the impact they can have in the situation.
- High quality manufacturers need to be championed and discuss with WEF to set up a partnership forum/meeting/platform where innovator companies can partner with large scale manufacturers. DCVMN needs to showcase capabilities in order to attract innovators to partner with DCVMs.
- Feedback from CEPI and GAVI is that while DCVMN has done surveys in the past, they don't think that the exercise was detailed enough. DCVMN secretariat has designed another survey that will be circulated by Benoit, info will be collected by DCVMN Secretariat and then presented to the stakeholders (CEPI, Gavi, BMGF etc.) in an anonymized manner.
- SJ received clarification from people who are involved in CEPI affairs, the money they have collected US\$8B+ in the EU, decision has been taken that this money has been assigned to big pharma. And WEF only dedicated towards DCVMN. How to untangle this situation?
- SDP is seeing that WEF has not raised any funding for this. The goal is to leverage our network. Many Multinationals are not funded by CEPI or even get an AMC; but, the WEF may have a direct line with officials from Pfizer and could have a direct line of contact will result in potential partnership.
- SJ is worried that AMC was there, the money was there for PCV and it was all directed towards COVID-19.
- RPG says that the idea of CEPI with COVAX is planning to fund 6 projects out of 64 proposals they have received. Several DCVMN members sent a proposal. The call has been extended until September 28<sup>th</sup>. These could be about partnerships or even creating own products. The Technical groups idea is to support with general documents that could help any developer regardless the funding by CEPI or the COVAX mechanism but rather provide vaccine safety guidelines for vaccine manufacturing. Clinical sites would also need funding potentially and

regulatory authorities are very important to be involved. RPG offered to get the needs of DCMVMs in this way which could be helpful to get more guidance in terms of clinical development for Covid19 vaccine. And will give feedback on what is discussed in these committees.

- AA and SDP say RPG help is valuable and clinical trial funding is good for sites. However, since we are an industry organization, we should be involved in the front, and center and more members of the networks should get opportunities in supplies.
- SDP, ACT-A discussion is ongoing and there are gaps. During the pledging conferences the donors do pledges and then decide where the money is going to. How to increase visibility for countries for COVID-19. Countries are facing struggles on disease front and it has also affected countries on the economics and lack of sudden revenue stream (i.e taxes). This is becoming an issue in ACT-A where a lot of the funding promised is coming but they put restrictions and is not coming to vaccines.
- IFPMA contacted DCVMN and documents were circulated to the members. Countries like USA or EU have laws that protect vaccine manufacturers and suppliers in case there are any SAEs experienced from vaccination. IFPMA is concerned because there are no laws about liability and indemnification, there are criminal prosecutions that can be done in countries against the companies. And therefore, we would like to flag to Gavi to mention vaccine related AEs that were not seen in the clinical trials, but rather seen in post-marketing administration. Want to include language into COVAX facility agreements to protect manufacturers to a certain extent. Not applicable to other vaccines but only for COVID-19 and to include this language in procurement contracts between Gavi and country.
- AA asks how to proceed? SDP says with the documents circulated, review it, and include criminal liability and criminal prosecution and drafts will be circulated and if they have any feedback that is specific to their countries that could be included in the language.
- AA presents, a basic on ACT-A, SWAT teams are the think tanks that help answer questions and giving insights to vaccine teams.
- 5 functional groups: R&D&M investment group, Technical review, Vaccine teams, SWAT teams (Enabling sciences, clinical development, Manufacturing regulatory advisory group), and RAG. Task forces for SWAT Team (Manufacturing: DP and DS scale up, supply chain, release assays)
- DP workshop on July 27<sup>th</sup> on COVAX facilities.
- Registration received for sub-committees:
  - Clinical: RE (Champion), RPG, DD, LD, MF, Yeong Ok Baik
  - Partnership and manufacturing: YV (champion), HJ, LS, VB, SD
  - QC: Sunil Gairola (champion), ST
- AA encourages more people to step in. SV will send out a call for members to join.
- YV gave a short digest on partnership: STI framework program (BRICS), Joint funding multilateral research cooperation. 18<sup>th</sup> august 2020 deadline. YV requested the members to give feedback on what is most interesting for the group to be included in the weekly digests.

Meeting was adjourned at 13:03

Next meeting will be (4<sup>th</sup>-6<sup>th</sup>) August at 12:00

Notes taken by Apoorv Kumar and edited by Sonia Villasenor